Ab Initio is engaged in identifying therapeutic antibodies that activate and inactivate G-protein coupled receptors. This category of receptor includes a rich landscape of clinically important targets, but the identification of biologic drugs that can specifically modulate their activity has proved historically difficult. The Company's current programs include targets important for cardiovascular disease, metabolic disorders, ophthalmology, and cancer.